
Twist Bioscience Corporation
TWST
Updated: 23/09/2026, 23:32:29
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
No summaries found.
- Share price
- $158.50
- Market cap
- $9.87B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Emily Marine Leproust
- Employees
- 979
- IPO date
- 31/10/2018
- Beta
- 2.22
- Last dividend
- $0.00
- Day range
- $157.41 – $166.35
- 52-week range
- $23.30 – $170.66
- 1-day performance
- -3.71%
- 1-year performance
- 580.26%
- Current drawdown (1Y)
- -7.13%
- CIK
- 0001581280
- CUSIP
- 90184D100
- ISIN
- US90184D1000
- Created
- 07/12/2025, 14:50:39
- Last update
- 23/09/2026, 23:32:29
Track Twist Bioscience Corporation with an AI analyst
See which prediction-market events move TWST, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Zacks Investment Research • STOCK • 12/06/2026, 11:26:07
Analyst Initiates Coverage on Twist Bioscience (NASDAQ:TWST) with 'Overweight' Rating
Market Data • Market Data • 11/06/2026, 13:15:59
Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?
Fool - Investing News • STOCK • 06/06/2026, 16:19:08
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
Seeking Alpha • STOCK • 26/05/2026, 13:07:05
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
Business Wire • STOCK • 08/05/2026, 11:08:00
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire • STOCK • 05/05/2026, 10:00:00
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 04/05/2026, 15:53:23
Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 10/03/2026, 19:00:15
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Seeking Alpha • STOCK • 18/02/2026, 16:54:56